Analysis of 2600 tumors could help match cancer patients to targeted treatments.
Category: biotech/medical – Page 1,901
The Royal Society is to create a network of disease modelling groups amid academic concern about the nation’s reliance on a single group of epidemiologists at Imperial College London whose predictions have dominated government policy, including the current lockdown.
It is to bring in modelling experts from fields as diverse as banking, astrophysics and the Met Office to build new mathematical representations of how the coronavirus epidemic is likely to spread across the UK — and how the lockdown can be ended.
The first public signs of academic tensions over Imperial’s domination of the debate came when Sunetra Gupta, professor of theoretical epidemiology at Oxford University, published a paper suggesting that some of Imperial’s key assumptions could be wrong.
A migrant worker in India dies after walking 200 km on the way back to his home [1].
Rural itinerant workers in China are being blocked from cities, kicked out of apartments and rejected by companies [2].
“Poverty will kill us before the virus” — Rajneesh, a migrant worker, walking 247Km on foot to his home [3].
I made a video on the possible treatments for COVID-19 and how it targets different components of SARS-CoV-2, the virus that causes it 😃
You can watch it here: https://youtu.be/DaXG3Qd8soo And let me know if you have questionsor suggestions 😃.
As the coronaviruspandemic sweeps across the United States, another invisible enemy is threatening America’s data security.
From stealing data to disseminating misinformation, hackers are taking advantage of the US at an especially vulnerable time during the war against the deadly outbreak.
As millions of Americans have been ordered to work from home to contain the spread of the virus, data is now being transmitted outside secure business networks, making it a treasure trove for hackers.
If new cells, with new DNA, RNA polymerases and nucleotides can be generated to replace the cells affected by the virus, the enzyme of the virus can be eliminated, and the virus will be unable to make copies of its RNA. This can be done by stimulating the stem cells to become cells with new DNA, RNA, proteins, and nucleotides. Stem Cell Neurotherapy sends therapeutic messages to the DNA inside the stem cells’ nucleus. DNA sends the information to the RNA molecules called messenger RNA. The transfer RNA synthesizes proteins to carry out the instructions given by messenger RNA templates for the stem cells to become new cells and tissues to replace those infected by the coronavirus. We have produced and developed Stem Cell Neurotherapy for COVID-19 patients. The therapy is designed to help the patients generate new cells in their lungs, liver, kidney, and other organs to replace those cells that have been infected by COVID-19. These new cells will eliminate the fever, coughing, headaches, breathing problems, and other symptoms related to COVID-19. More details are at: Stem Cell Neurotherapy on Facebook…
How did a U.S. patient in a New Jersey hospital become the first presumed Covid 19 respiratory failure patient in the world to receive stem cell exosomes? Get the inside scoop!
Cancer cells have the extraordinary evolutionary potential to adapt and acquire resistance to most conventional and targeted therapies. In a new study, Lin et al., develop a systematic approach to identify combination therapies that produce cancer traps, in which evading the first drug makes the cancer vulnerable to the second.
In addition to self isolation, widespread testing to identify asymptomatic spreaders is needed. YaleNews:
The conclusion of a new Yale-led study is clear: Without dramatic action, there won’t be enough beds for the sickest COVID-19 patients.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.
ScienceDirect ® is a registered trademark of Elsevier B.V.